Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SARS-CoV Spike anticorps

Cet anticorps Souris Monoclonal détecte spécifiquement SARS-CoV Spike dans . Il présente une réactivité envers SARS Coronavirus (SARS-CoV).
N° du produit ABIN7794776

Aperçu rapide pour SARS-CoV Spike anticorps (ABIN7794776)

Antigène

Voir toutes SARS-CoV Spike (SARS-CoV S) Anticorps
SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Reactivité

  • 51
  • 16
  • 1
SARS Coronavirus (SARS-CoV)

Hôte

  • 42
  • 9
  • 1
Souris

Clonalité

  • 42
  • 10
Monoclonal

Conjugué

  • 31
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp SARS-CoV Spike est non-conjugé

Application

Veuillez nous consulter SVP

Clone

COV1-100
  • Fonction

    Anti-SARS-CoV-1, Spike (Clone COV1-100)-Purified No Carrier Protein

    Specificité

    COV1-100 targets the prefusion spike protein (S2) of SARS-CoV-1 and SARS-CoV- 2. Antigen Distribution Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-100 monoclonal antibody targets the spike protein of both SARS-CoV-1 and SARS- CoV-2, demonstrating cross-reactivity. However, it does not block the ACE2 receptor and does not function as a neutralizer. The epitope targeted by COV1-100 is unknown, which indicates that more research is needed to determine its binding site and potential role in viral inhibition. Despite not being a neutralizer, COV1-100 might play a role in modulating the immune response or could be useful in combination with other antibodies that have neutralizing capabilities, providing a broader spectrum of antiviral activity.

    Purification

    Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

    Pureté

    >=90 % monomer by analytical SEC and SDS-Page

    Isotype

    IgG1 lambda
  • Restrictions

    For Research Use only
  • Concentration

    1 μg/mL

    Buffer

    This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

    Agent conservateur

    Without preservative

    Stock

    4 °C,-80 °C

    Stockage commentaire

    This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.
  • Antigène

    SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

    Autre désignation

    SARS-CoV Spike

    Classe de substances

    Viral Protein
Vous êtes ici:
Chat with us!